Mode
Text Size
Log in / Sign up
Phase 3 Completed N=769 Randomized Double-blind Treatment

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Source: ClinicalTrials.gov NCT02275780 ↗
Enrolled (actual)
769
Serious AEs
12.3%
Results posted
Oct 2018
Primary outcomePrimary: Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48 — 83.8; 79.9 Percentage of participants
◆ Published Evidence
Established
30citations · ~15 / year
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
The lancet. HIV · 2024 · Open access · Likely link

Summary

To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1. Eligible participants who are deriving benefit will continue in Study Extension 2 to receive the doravirine-containing regimen open label until doravirine becomes locally available or for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.

Linked Publications (5)

  • Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
    The lancet. HIV · 2024 · 30 citations · Open access · Likely link
  • Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.
    Journal of acquired immune deficiency syndromes (1999) · 2025 · 2 citations · Open access · Likely link
  • Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen.
    Open forum infectious diseases · 2025 · 1 citation · Open access · Likely link
  • Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
    Journal of acquired immune deficiency syndromes (1999) · 2026 · 0 citations · Open access · Likely link
  • Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials.
    Open Forum Infectious Diseases · 2025 · 0 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48
83.8; 79.9
SECONDARY
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96
73.1; 66.0
SECONDARY
Change From Baseline in Mean CD4+ T-cell Count at Week 48
192.7; 185.6
SECONDARY
Change From Baseline in Mean CD4+ T-cell Count at Week 96
224.1; 206.7
SECONDARY
Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48
91.10; 91.76; -4.51; 9.92 <0.0001 sig
SECONDARY
Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48
113.34; 114.44; -5.30; 13.75 <0.0001 sig
SECONDARY
Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48
43.58; 43.27; 3.94; 4.15
SECONDARY
Mean Change From Baseline in Fasting Total Cholesterol at Week 48
156.92; 157.71; -1.37; 17.90
SECONDARY
Mean Change From Baseline in Fasting Triglyceride at Week 48
111.16; 117.02; -3.14; 21.97
SECONDARY
Percentage of Participants With Any Adverse Event
84.6; 82.8
SECONDARY
Percentage of Participants With Any Serious Adverse Event
7.0; 8.6
SECONDARY
Percentage of Participants With Any Drug-related Adverse Event
32.1; 32.1
SECONDARY
Percentage of Participants With Any Drug-related Serious Adverse Event
0.3; 0.3
SECONDARY
Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event
1.6; 3.4
SECONDARY
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48
83.3; 79.1
SECONDARY
Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96
72.0; 64.4

Eligibility Criteria

Inclusion Criteria

  • Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
  • Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretroviral agents.
  • Is considered clinically stable with no signs or symptoms of active infection for at least 2 weeks prior to the start of treatment.
  • Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate a partner because they are not of reproductive potential, or agree to practice abstinence or use acceptable contraception for up to 14 days after the last dose of study drug.
  • Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96 visit, 2) derived benefit from participation through Week 96 in the opinion of the investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of treatment with the Study Extension regimen.
  • Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192 visit, 2) derived benefit from participation through Week 192 in the opinion of the investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with the Study Extension regimen.

Exclusion Criteria

  • Uses or has had a recent history of using recreational or illicit drugs.
  • Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1.
  • Has documented or known resistance to study drugs including doravirine, darunavir, ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.
  • Has participated in a study with an investigational compound/device within the prior month, or anticipates doing so during this study.
  • Has used systemic immunosuppressive therapy or immune modulators within the prior 30 days, or anticipates doing so during this study.
  • Has significant hypersensitivity or other contraindication to any of the components of the study drugs.
  • Has a current (active) diagnosis of acute hepatitis due to any cause.
  • Is pregnant, breastfeeding or expecting to conceive at any time during the study.
  • Female who expects to donate eggs, or male who expects to donate sperm at any time during the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02275780) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search